This protocol covers the next treatment step for patients with fibrous dysplasia of bone who have persistent bone pain without neuropathic features — no burning or stabbing quality — and for whom first-line NSAID therapy has not provided sufficient pain relief.
The patient experiences bone pain attributable to fibrous dysplasia. Neuropathic pain characteristics — burning or stabbing pain — are absent, placing this presentation on a non-neuropathic analgesic pathway. Pain has not resolved adequately with first-line therapy.
The initial treatment for this non-neuropathic bone pain pattern is NSAIDs, considered when benefits outweigh cardiovascular, renal, and gastrointestinal risks. Escalation to this protocol is triggered when bone pain relief has not been achieved with that approach.
When bone pain persists at moderate-to-severe intensity, intravenous bisphosphonate therapy is the recommended next step. The full structured regimen — including agent selection, dosing schedule, and response-guided decision points — is available in the complete protocol.
The primary target is a meaningful improvement in bone pain VAS score and sustained pain relief, with subsequent treatment decisions guided by the response to initial therapy.
For analgesics, consider paracetamol/acetaminophen as first line, followed by NSAIDs, if benefits outweigh cardiovascular, renal and gastro-intestinal risk.
Bisphosphonates are proposed for persistent, moderate to severe pain as defined by VAS score of > 3/10.
Intravenously administered pamidronate and zoledronate can be equally considered (Table 3).
The aim of initial dosing is to establish whether bisphosphonates are effective in providing pain relief.
Subsequent dosing intervals should be determined according to need for analgesia and response to previous doses.
View source ↗